The overall aim of this proposal is to continue the role of UTMDACC as a Research Base in the Community Clinical Oncology Program (CCOP), by accomplishing the following objectives: 1) To provide NCI-approved treatment and cancer control protocols for CCOP participants; 2) To integrate the CCOP network into the clinical research program of UTMDACC; 3) To maintain the data management and quality assurance systems necessary to ensure data of the highest quality in this collaborative research program; 4) To develop cancer control programs which will generate a series of research protocols for CCOP investigators. The MDACC CCOP network will consist of thirty-four CCOPs in 24 states, four of which are new Minority CCOPS. It is estimated that these CCOPs will provide 537 patients (credits) for treatment protocols and 2241 subjects or 910 credits for cancer control protocols annually. Mechanisms for the development of cancer control protocols based on MDACC or CCOP concepts have been developed, utilizing CCOP staff as Principal Investigators (PI) or Co-PIs. Communication concerning the development of trials is accomplished by interactive meetings, a monthly newsletter with surveys, and a proposed electronic mail system. Data management using the MDACC computerized Protocol Data Management System has been adapted to multi-institutional trials, including a protocol data form tracking system. A complete quality assurance system has been devised. This includes a continuous monitoring of CCOP performance for eligibility, evaluability, data quality, and data timeliness. On-site audits will be performed on each CCOP every 18 months. Review of all major resources will be performed to assure concordance between MDACC and CCOP evaluations. Standardized forms and procedure manuals will be designed for all cancer control studies and appropriate quality assurance measures devised. The goal of the CCOP network is to optimize interactions between MDACC and CCOP investigators in the research of therapeutic and prevention interventions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045809-08
Application #
2092032
Study Section
Special Emphasis Panel (SRC (48))
Project Start
1987-09-01
Project End
1996-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Levin, Victor A; Ictech, Sandra E; Hess, Kenneth R (2018) Clinical importance of eflornithine (?-difluoromethylornithine) for the treatment of malignant gliomas. CNS Oncol 7:CNS16
Narayan, Hari K; Wei, Wei; Feng, Ziding et al. (2017) Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study. Open Heart 4:e000524
Spencer, Christine N; Lopez, Gabriel; Cohen, Lorenzo et al. (2016) Nurse and patient characteristics predict communication about complementary and alternative medicine. Cancer 122:1552-9
Siefker-Radtke, Arlene O; Campbell, Matthew T; Munsell, Mark F et al. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89:83-9
Kee, Bryan K; Morris, Jeffrey S; Slack, Rebecca S et al. (2015) A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer 23:661-70
Mitri, Zahi; Karakas, Cansu; Wei, Caimiao et al. (2015) A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33:890-4
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J et al. (2015) Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15:152-8
Bilen, Mehmet Asim; Johnson, Marcella M; Mathew, Paul et al. (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121:69-76

Showing the most recent 10 out of 43 publications